A randomized, double-blind, placebo-controlled, parallel-group, clinical trial designed to assess the safety of ciclesonide, applied as a nasal spray at three dose levels, 200 microg, 100 microg or 25 microg once daily for six weeks, in the treatment of perennial allergic rhinitis (PAR) in pediatric patients 2-5 years of age.

Trial Profile

A randomized, double-blind, placebo-controlled, parallel-group, clinical trial designed to assess the safety of ciclesonide, applied as a nasal spray at three dose levels, 200 microg, 100 microg or 25 microg once daily for six weeks, in the treatment of perennial allergic rhinitis (PAR) in pediatric patients 2-5 years of age.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs Ciclesonide (Primary)
  • Indications Perennial allergic rhinitis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors ALTANA Pharma; AstraZeneca
  • Most Recent Events

    • 05 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top